Benda Pharmaceutical, Inc. Announces Resignation of Board Member

HUBEI PROVINCE, China, June 19 /Xinhua-PRNewswire-FirstCall/ -- Benda Pharmaceutical, Inc. , a China-based pharmaceutical company producing both Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, today announced that Charles Mo has resigned from the Board of Directors of Benda Pharmaceutical, Inc., effective June 15, 2008. Mr. Mo joined the Board in 2007 and served as an independent director as well as Chairman of the Audit Committee.

"On behalf of the board of directors and management team, I would like to thank Mr. Mo for his many contributions and dedicated service to the Company. His leadership and vision have been invaluable to the Company and we wish him well in his future endeavors," said Charles Wan, Chief Executive Officer of Benda Pharmaceutical. "Meanwhile, the Board is conducting a thorough replacement search."

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer.

Safe Harbor Statement

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

CONTACT: Christine Duan of Integrated Corporate Relations, Inc. at
+1-203-682-8200, for Benda Pharmaceutical, Inc.

Web site: http://www.bendapharma.com/